MedTrace Logo

A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age

NCT00988533 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-04-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the bioavailability of 0.5% ivermectin cream in a pediatric population aged 6 months to 3 years.

Conditions

  • Head Lice

Interventions

DRUG

0.5% Ivermectin Cream

Topical 0.5% ivermectin cream applied to scalp and hair on day 1

Sponsors & Collaborators

  • Topaz Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Sanofi Topaz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
3 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00988533 on ClinicalTrials.gov